# Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer

> **NCT00193362** · PHASE3 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 200 (—)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT00193362
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2005-06
- **Final completion:** 2007-09
- **Target enrollment:** 200 (—)
- **Last updated:** 2010-07-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193362, "Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00193362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*